Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and birb 796

lapatinib has been researched along with birb 796 in 7 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(birb 796)		Trials
(birb 796)		Recent Studies (post-2010) (birb 796)
1,9193051,442137580

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)birb 796 (IC50)
Mitogen-activated protein kinase 13Homo sapiens (human)0.1057
Mitogen-activated protein kinase kinase kinase 7Homo sapiens (human)0.9
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)10
Serine/threonine-protein kinase 10Homo sapiens (human)1
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)1
Epidermal growth factor receptorHomo sapiens (human)3.8
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)1.4
High affinity nerve growth factor receptorHomo sapiens (human)0.58
Heat shock protein beta-1Homo sapiens (human)0.058
Protein kinase C beta typeHomo sapiens (human)6.9
Tyrosine-protein kinase LckHomo sapiens (human)2.1
Tyrosine-protein kinase YesHomo sapiens (human)8.9
Tyrosine-protein kinase LynHomo sapiens (human)0.96
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.515
Tyrosine-protein kinase HCKHomo sapiens (human)1.7
Platelet-derived growth factor receptor betaHomo sapiens (human)6.2
Tyrosine-protein kinase FgrHomo sapiens (human)8.5
Mast/stem cell growth factor receptor KitHomo sapiens (human)1
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.0834
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.625
Ephrin type-A receptor 1Homo sapiens (human)0.63
Fibroblast growth factor receptor 4Homo sapiens (human)7
Mitogen-activated protein kinase 1Homo sapiens (human)9.2
Ephrin type-A receptor 2Homo sapiens (human)0.16
Ephrin type-A receptor 3Homo sapiens (human)1.1
Ephrin type-A receptor 8Homo sapiens (human)1
Ephrin type-B receptor 2Homo sapiens (human)0.58
Tyrosine-protein kinase receptor Tie-1Homo sapiens (human)1
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.27
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.34
Tyrosine-protein kinase FRKHomo sapiens (human)1
Mitogen-activated protein kinase 8Homo sapiens (human)1
Mitogen-activated protein kinase 9Homo sapiens (human)0.2989
Cyclin-dependent kinase 8Homo sapiens (human)1
Glycogen synthase kinase-3 betaHomo sapiens (human)1.06
Tyrosine-protein kinase BlkHomo sapiens (human)1
Mitogen-activated protein kinase 12Homo sapiens (human)0.2298
Mitogen-activated protein kinase 10Homo sapiens (human)1.2
Ephrin type-B receptor 3Homo sapiens (human)9.4
Ephrin type-A receptor 5Homo sapiens (human)0.09
Ephrin type-B receptor 4Homo sapiens (human)0.9
Ephrin type-B receptor 1Homo sapiens (human)0.11
Ephrin type-A receptor 4Homo sapiens (human)0.07
Cyclin-dependent-like kinase 5 Homo sapiens (human)1
Angiopoietin-1 receptorHomo sapiens (human)0.5125
Focal adhesion kinase 1Homo sapiens (human)2
Protein kinase C delta typeHomo sapiens (human)1.9
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)1
Protein-tyrosine kinase 2-betaHomo sapiens (human)0.7
Ephrin type-A receptor 7Homo sapiens (human)1
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1Homo sapiens (human)0.9
Mitogen-activated protein kinase 11Homo sapiens (human)0.256
NT-3 growth factor receptorHomo sapiens (human)1
Mitogen-activated protein kinase 14Homo sapiens (human)0.0674
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.525
Discoidin domain-containing receptor 2Homo sapiens (human)0.2707
Misshapen-like kinase 1Homo sapiens (human)0.04
STE20-like serine/threonine-protein kinase Homo sapiens (human)1
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)1
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)1
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)1

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Asantewaa, G; Ciesla, JH; Dewhurst, S; Harris, IS; Leach, J; Lutz, MM; Monaghan, M; Munger, J; Raymonda, MH; Schafer, XL; Smorodintsev-Schiller, LA; Takimoto, T1

Other Studies

7 other study(ies) available for lapatinib and birb 796

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
    Virology, 2022, Volume: 566

    Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Benzoquinones; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Discovery; Drug Synergism; High-Throughput Screening Assays; Humans; Lactams, Macrocyclic; Lapatinib; Naphthalenes; Phenylurea Compounds; Pyrazoles; RNA, Viral; SARS-CoV-2; Vero Cells; Virus Replication

2022